Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS).
“The OlympiA trial examines adding one year of the oral PARP inhibitor olaparib after completion of standard treatment for higher risk breast cancer in individuals with pathogenic germline BRCA variants,” said Judy E. Garber, MD, MPH, chief of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute and the presenter of the study.
OlympiA is a multicenter, double-blind study in which 1,836 patients with BRCA-positive, HER2-negative breast cancer were randomly assigned (1:1) to receive either olaparib or placebo for one year following completion of chemotherapy, surgery, and radiation. Based on previous results from the trial, Olaparib was approved in 2022 in the adjuvant setting for certain patients with HER2-negative, BRCA-positive breast cancer.
“Data from the third prespecified interim analysis presented here provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2,” said Garber.
After a median follow-up of 6.1 years, patients treated with olaparib continued to show significant improvements in survival outcomes, in both triple-negative breast cancer as well as estrogen receptor (ER)-positive breast cancer subgroups. Both of the study’s primary endpoints—invasive disease-free survival and distant disease-free survival—were achieved, with olaparib reducing the risk of each by 35%.
At six years, 79.6% of olaparib-treated patients remained free of invasive recurrence and 83.5% remained free of distant recurrence, compared to 70.3% and 75.7%, respectively, in the placebo group.
